Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477487 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
A Phase 1 study of Osteoarthritis, Knee, sponsored by Xalud Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03477487 is a Phase 1 study of Osteoarthritis, Knee that has completed, run by Xalud Therapeutics. The registered enrollment target is 32 participants, below the 580-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03477487, a Phase 1 study of Osteoarthritis, Knee, has completed, sponsored by Xalud Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the Treatment of Osteoarthritic Pain.
Conditions Studied
Interventions
- BIOLOGICAL XT-150
Study Locations (1)
California
- Neurovations (Napa Pain Institute) - Napa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477487
The ClinicalTrials.gov registry entry for NCT03477487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 580-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower). The listed sponsor is Xalud Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 1 intervention - of which XT-150 is the first listed.
NCT03477487 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03477487 about?
NCT03477487 is a clinical study titled "Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain". Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the Treatment of Osteoarthritic Pain.
What is the current status of trial NCT03477487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-06-08. Estimated completion is 2019-09-30.
What conditions does trial NCT03477487 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee.
What interventions are being tested in trial NCT03477487?
The interventions under investigation include: XT-150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03477487?
This trial is sponsored by Xalud Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03477487 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
CBD for Knee Osteoarthritis
RECRUITING · Phase 1
-
Oral Steroid Taper After Total Knee Arthroplasty
RECRUITING · Phase 1
-
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
ACTIVE NOT RECRUITING · Phase 1
-
Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
ACTIVE NOT RECRUITING · Phase 1
-
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.